Cancer Family
Genitourinary System Neoplasm
CI-CAN-00000018Explore in graph →
Non-malignant3,856 active trials61 approved drugs307 evidence items
- NCIt
- C156482
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000018Explore in graph →
Clinical trials
17,398 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02560012 | Personalized Targeted Inhibitors Treatment in Renal Cell Cancer | terminated | Phase 2 | 4 | The University of Texas Health Science Center, HoustonOTHER | 1 | Oct 12, 2018 | clinicaltrials |
| NCT02605863 | Enzalutamide for Bladder Cancer Chemoprevention | terminated | Phase 2 | 1 | University of RochesterOTHER | 1 | Oct 3, 2018 | clinicaltrials |
| NCT00670046 |
| Valproic Acid in Treating Patients With Progressive, Non-Metastatic Prostate Cancer |
| terminated |
| Phase 2 |
| 15 |
| Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER |
| 1 |
| Sep 28, 2018 |
| clinicaltrials |
| NCT00322881 | Carboplatin and Paclitaxel in Elderly Women With Newly Diagnosed Ovarian, Peritoneal, or Fallopian Cancer | terminated | Phase 2 | 12 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 10, 2018 | clinicaltrials |
| NCT00910000 | Vorinostat, Carboplatin and Gemcitabine in Women With Recurrent, Platinum-Sensitive Ovarian Cancer | terminated | Phase 1 / Phase 2 | 15 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 10, 2018 | clinicaltrials |
| NCT00953576 | Ketoconazole, Hydrocortisone, Dutasteride and Lapatinib (KHAD-L) in Prostate Cancer(KHLAD) | terminated | Phase 1 / Phase 2 | 11 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 4, 2018 | clinicaltrials |
| NCT00527124 | Docetaxel and Prednisone With or Without Cediranib in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy | terminated | Phase 2 | 57 | National Cancer Institute (NCI)NIH | 1 | Aug 9, 2018 | clinicaltrials |
| NCT01439542 | FASTR: Fairly Brief Androgen Suppression and Stereotactic Radiotherapy for High Risk Prostate Cancer(FASTR) | terminated | Phase 2 | 19 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 1 | Aug 9, 2018 | clinicaltrials |
| NCT00089102 | Gemcitabine and Irinotecan in Treating Patients With Locally Advanced Unresectable or Metastatic Kidney Cancer | terminated | Phase 2 | 9 | Medical University of South CarolinaOTHER | 1 | Jul 16, 2018 | clinicaltrials |
| NCT01335204 | Ph Ib/IIa Study of Cabazitaxel Plus Bavituximab in Castration-resistant Prostate Cancer | terminated | Phase 1 / Phase 2 | 4 | Medical University of South CarolinaOTHER | 1 | Jul 13, 2018 | clinicaltrials |
| NCT00089128 | Gemcitabine and Irinotecan in Treating Patients With Locally Advanced or Metastatic Bladder Cancer | terminated | Phase 2 | 16 | Medical University of South CarolinaOTHER | 1 | Jul 12, 2018 | clinicaltrials |
| NCT00090870 | PEG-Interferon Alfa-2b, Sargramostim, and Thalidomide in Treating Patients With Metastatic Kidney Cancer | terminated | Phase 2 | 10 | Medical University of South CarolinaOTHER | 1 | Jul 12, 2018 | clinicaltrials |
| NCT00268450 | Cisplatin, Bevacizumab, and Gemcitabine Followed by Surgery, Bevacizumab, and Paclitaxel in Treating Patients With Locally Advanced Nonmetastatic Bladder Cancer That Can Be Removed By Surgery | terminated | Phase 2 | 21 | Medical University of South CarolinaOTHER | 1 | Jul 12, 2018 | clinicaltrials |
| NCT00634582 | Paricalcitol in Treating Patients With Advanced Prostate Cancer and Bone Metastases | terminated | Phase 2 | 2 | Wake Forest University Health SciencesOTHER | 1 | Jul 6, 2018 | clinicaltrials |
| NCT02423954 | Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus)(NivoPlus) | terminated | Phase 1 / Phase 2 | 33 | Western Regional Medical CenterOTHER | 1 | Jul 2, 2018 | clinicaltrials |
| NCT00058448 | S0224, Docetaxel in Treating Patients With Locally Advanced or Metastatic Penile Cancer (TERMINATED) | terminated | Phase 2 | 1 | SWOG Cancer Research NetworkNETWORK | 1 | Jun 28, 2018 | clinicaltrials |
| NCT01482949 | A Rollover Protocol for Subjects Previously Treated With AGS-003 | terminated | Phase 2 | 2 | Argos TherapeuticsINDUSTRY | 1 | Jun 27, 2018 | clinicaltrials |
| NCT02215161 | Selinexor in Treating Patients With Abiraterone Acetate and/or Enzalutamide Refractory Metastatic Castration-Resistant Prostate Cancer | terminated | Phase 2 | 14 | University of California, San FranciscoOTHER | 1 | Jun 26, 2018 | clinicaltrials |
| NCT02626754 | A Prospective Study on Sunitinib as First Line Therapy for Advanced/Metastatic Renal Cell Carcinoma in Asian Population | terminated | Phase 2 | 13 | vghtpe userOTHER_GOV | 1 | Jun 26, 2018 | clinicaltrials |
| NCT01845792 | Study of Abiraterone Acetate and Prednisone in Combination With Cabazitaxel in Patients With Prostate Cancer | terminated | Phase 2 | 7 | University of Colorado, DenverOTHER | 1 | Jun 4, 2018 | clinicaltrials |
| NCT00866723 | Avastin in Patients With Epithelial Ovarian, Primary Peritoneal Serous or Fallopian Tube Cancer | terminated | Phase 2 | 5 | Beth Israel Deaconess Medical CenterOTHER | 1 | May 22, 2018 | clinicaltrials |
| NCT01857817 | Efficacy and Safety Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer | terminated | Phase 2 | 35 | Vicus TherapeuticsINDUSTRY | 1 | Apr 26, 2018 | clinicaltrials |
| NCT01331824 | Trial of Amrubicin as Second-Line Therapy in Patients With Advanced/Metastatic Refractory Urothelial Carcinoma | terminated | Phase 2 | 22 | Matthew GalskyOTHER | 1 | Apr 23, 2018 | clinicaltrials |
| NCT00005029 | Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer | terminated | Phase 2 | — | Gynecologic Oncology GroupNETWORK | 2 | Apr 12, 2018 | clinicaltrials |
| NCT00096187 | Pemetrexed Disodium in Treating Patients With Recurrent or Persistent Low-Risk Gestational Trophoblastic Tumor After a Molar Pregnancy | terminated | Phase 2 | 55 | Gynecologic Oncology GroupNETWORK | 1 | Apr 12, 2018 | clinicaltrials |
| NCT01773889 | A Trial of Intravenous Denileukin Diftitox Plus Subcutaneous Pegylated IFNα-2A in Stage III or IV Ovarian Cancer | terminated | Phase 2 | 2 | The University of Texas Health Science Center at San AntonioOTHER | 1 | Apr 10, 2018 | clinicaltrials |
| NCT01234519 | A Phase I/II Trial of AEZS-108 in Urothelial Cancer Patients Who Failed Platinum-chemotherapy | terminated | Phase 1 / Phase 2 | 12 | AEterna ZentarisINDUSTRY | 1 | Mar 15, 2018 | clinicaltrials |
| NCT00860158 | Neoadjuvant Dasatinib Plus LHRH Analogue Therapy in High-Risk Localized Prostate Cancer | terminated | Phase 2 | 1 | Noah Hahn, M.D.OTHER | 1 | Mar 14, 2018 | clinicaltrials |
| NCT00408070 | Bevacizumab Study With Carboplatin & Paclitaxel in Ovarian, Fallopian Tube or Primary Peritoneal Cancer | terminated | Phase 2 | 5 | UConn HealthOTHER | 1 | Mar 8, 2018 | clinicaltrials |
| NCT03456401 | Third Line TKI After 2 TKIs in Patients With mRCC (Tokio Study)(TOKIO) | terminated | Phase 2 | 18 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Mar 7, 2018 | clinicaltrials |
| NCT02101684 | Orteronel (TAK-700) in Metastatic or Advanced Non-resectable Granulosa Cell Ovarian Tumors. The Greko II Study.(Greko II) | terminated | Phase 2 | 10 | Grupo Español de Tumores Huérfanos e InfrecuentesOTHER | 1 | Mar 5, 2018 | clinicaltrials |
| NCT02606123 | Safety and Anti-Tumor Study of Oral EPI-506 for Patients With Metastatic Castration-Resistant Prostate Cancer | terminated | Phase 1 / Phase 2 | 28 | ESSA PharmaceuticalsINDUSTRY | 2 | Mar 1, 2018 | clinicaltrials |
| NCT01936974 | (PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma(PGA) | terminated | Phase 2 | 7 | Western Regional Medical CenterOTHER | 1 | Feb 20, 2018 | clinicaltrials |
| NCT00638378 | Study of Ruxolitinib (INCB018424) Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer | terminated | Phase 2 | 22 | Incyte CorporationINDUSTRY | 1 | Feb 12, 2018 | clinicaltrials |
| NCT00003516 | Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer | terminated | Phase 2 | 16 | Burzynski Research InstituteOTHER | 1 | Feb 5, 2018 | clinicaltrials |
| NCT02479490 | PRednisone Plus EVerolimus in Patients With Metastatic Renal Cell Cancer After Failure of VEGFR -TKI(PREV) | terminated | Phase 2 | 8 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Jan 16, 2018 | clinicaltrials |
| NCT00574951 | AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | terminated | Phase 2 | 23 | Gynecologic Oncology GroupNETWORK | 1 | Jan 11, 2018 | clinicaltrials |
| NCT01573156 | Vascular Targeted Photodynamic Therapy T1a Renal Tumours(KCM201) | terminated | Phase 1 / Phase 2 | 5 | University of OxfordOTHER | 1 | Jan 10, 2018 | clinicaltrials |
| NCT00585052 | A Phase II Study of Interaction of Lovastatin and Paclitaxel For Patients With Refractory or Relapsed Ovarian Cancer | terminated | Phase 2 | 11 | University of IowaOTHER | 1 | Jan 5, 2018 | clinicaltrials |
| NCT00331422 | Carboplatin, Paclitaxel, and Surgery in Treating Patients With Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer | terminated | Phase 2 | 7 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 28, 2017 | clinicaltrials |
| NCT00602446 | Deferasirox in Treating Patients With Iron Overload After Undergoing a Donor Stem Cell Transplant | terminated | Phase 2 | 4 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 28, 2017 | clinicaltrials |
| NCT00652899 | Allogeneic Natural Killer Cells in Patients With Recurrent Ovarian Cancer, Fallopian Tube, and Primary Peritoneal Cancer | terminated | Phase 2 | 14 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 28, 2017 | clinicaltrials |
| NCT00903630 | Lenalidomide and Doxorubicin Hydrochloride Liposome in Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | terminated | Phase 1 / Phase 2 | 15 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 28, 2017 | clinicaltrials |
| NCT00003532 | Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Ovarian Cancer | terminated | Phase 2 | 7 | Burzynski Research InstituteOTHER | 1 | Dec 12, 2017 | clinicaltrials |
| NCT00003533 | Antineoplaston Therapy in Treating Patients With Metastatic Prostate Cancer | terminated | Phase 2 | 12 | Burzynski Research InstituteOTHER | 1 | Dec 12, 2017 | clinicaltrials |
| NCT00348816 | Docetaxel, Radiation Therapy, and Prednisone in Treating Patients Who Have Undergone Surgery For Prostate Cancer | terminated | Phase 2 | 21 | The University of Texas Health Science Center at San AntonioOTHER | 1 | Dec 8, 2017 | clinicaltrials |
| NCT01075412 | FLT PET Imaging for Cervical Cancer | terminated | Phase 2 | 6 | University of IowaOTHER | 1 | Dec 2, 2017 | clinicaltrials |
| NCT01200810 | Bicalutamide and RO4929097 in Treating Patients With Previously Treated Prostate Cancer | terminated | Phase 2 | 10 | National Cancer Institute (NCI)NIH | 1 | Dec 2, 2017 | clinicaltrials |
| NCT00477087 | Phase II GM-CSF Plus Mitoxantrone in Hormone Refractory Prostate Cancer | terminated | Phase 2 | 10 | Stanford UniversityOTHER | 1 | Nov 29, 2017 | clinicaltrials |
| NCT02122003 | Second Line Sorafenib After Pazopanib in Patients With RCC(SOAP) | terminated | Phase 2 | 16 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Nov 22, 2017 | clinicaltrials |
Data updated 24 days agoSource updated Oct 12, 2018source: clinicaltrials